Biotech IV Monitor

TARS — Tarsus Pharmaceuticals Inc.

$2.5B market cap · 3 upcoming readouts tracked

Clinical trial readout dates for Tarsus Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.

Next readoutDecember 2026in ~1 month
Upcoming readouts3none in Phase 3
Market cap$2.5B
Cash & investments$310M~0 quarters at last loss rate
Recent 8-K filings1latest 2026-11-03

Upcoming readouts

Phase 2 lotilaner
Ocular Rosacea · NCT07443202
December 2026
Enrolling
Phase 2 TP-05 (lotilaner) Low Dose
Lyme Disease · NCT07562087
October 2027
Ongoing
Phase 2 TP-06
Persistent Corneal Epithelial Defect · NCT07886268
July 2028
Recruiting

Cash position

Tarsus Pharmaceuticals Inc. reported $310M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-03). Its net loss for that quarter was $668M; at that rate the cash would last about 0 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-03

Companies working on similar indications

Discussion

No messages yet. If you follow TARS, you can start the conversation.
Track TARS in real time
See live implied volatility for TARS and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on TARS
Contact — questions or corrections about TARS: dukeupt@gmail.com